mortality/aging
• mean survival time of double mutants is 41 weeks compared to 55 weeks for KrasLA+/-, Dmtf1-sufficient mice
|
neoplasm
• ~30% of mice develop thymic lymphomas
|
• 20-30% of animals develop tail papillomas
|
• one case of cholangiocarcinoma was observed
|
• <5% of animals show distant metastases (liver/intr-abdominal or leg) of lung tumors, while no metastases are observed in KrasLA+/-, Dmtf1-sufficient mice
|
• one case of neurofibroma was observed
|
• one case of osteosarcoma was observed
|
• ~50% of largest tumors are well, moderately, or poorly differentiated adenocarcinomas, with signs of intrabronchial or intravascular invasion
|
• all mice develop lung adenomas or lung adenocarcinomas
|
• greater than 50% of mice develop lung carcinomas by 40 weeks of age, and tumors are significantly larger than those found in KrasLA+/- single mutants
• number of tumor nodules increase as animals become sick, with trend to increased nodule size
|
• tumorigenesis is accelerated relative to heterozygous Kras, wild-type Dmtf1 mice
|
integument
• 20-30% of animals develop tail papillomas
|
endocrine/exocrine glands
• ~30% of mice develop thymic lymphomas
|
liver/biliary system
• one case of cholangiocarcinoma was observed
|
skeleton
• one case of osteosarcoma was observed
|
nervous system
• one case of neurofibroma was observed
|
respiratory system
• ~50% of largest tumors are well, moderately, or poorly differentiated adenocarcinomas, with signs of intrabronchial or intravascular invasion
|
• all mice develop lung adenomas or lung adenocarcinomas
|
• greater than 50% of mice develop lung carcinomas by 40 weeks of age, and tumors are significantly larger than those found in KrasLA+/- single mutants
• number of tumor nodules increase as animals become sick, with trend to increased nodule size
|